TEIS - UK Telemedicine and E-health Information Service
TEIS - UK Telemedicine and E-health Information Service: "This site is updated as we receive information from the telemedicine and e-health community. The objectives of TEIS are to bring together those working in the field of telemedicine, telecare and ehealth; to encourage them to share information and experience; and to provide an information resource on telemedicine activity in the UK. The Telemedicine and E-health Information Service is run by the University of Portsmouth. "
Minister intervenes in row over drugs to treat Alzheimer's
Guardian Unlimited | The Guardian : "James Meikle, health correspondent
The health minister Stephen Ladyman has intervened in the growing row over plans by NHS advisers to stop the routine prescription of four drugs to treat Alzheimer's disease.
He wants to ensure that they recognise the social implications of withdrawing official support for such drugs, even if they do not regard them as clinically cost-effective."
Connected Home Care
Connected Home Care "Connected Home Care, organised by HSA Conferences and Junction, will take place on 15 June 2005 in London to promote provision of care services to the ill and elderly in private homes by new information communication technologies. The one-day conference will provide an opportunity to bring together all of the key players within the healthcare sector – academic, research, health, social and suppliers – in a push to really drive the market forward and into the mainstream.
The conference will address both the financial and social benefits and demands of adopting these services – in line with the government’s objective that Connected Home Care services will be made available in all homes that require them by 2010."
UK eHealth Association
UK eHealth Association - Association News October 2000: Publish a newsletter to keep members up to date with telemedicine developments.
Google Search: tunstall emergency communications technology
Google Search: tunstall emergency communications technology The main providers of tracking and emergency communications technology to local authority housing and social services already, are now looking at the domestic, private market....
Emergency Response Systems and other products by Tunstall include:DDA compliant door panel User Alert Pager
Pillow Alert solution
Sounder Beacons
Environmental Control Solutions
Big Button Phones
Call Points
Remote Door Controllers
Inductive Loops
Video identification solutions
Of especial interest for carers of persons with dementia is the:
"Wandering clientProvides an early warning by alerting the 24 hour response centre that the user has
left their home and not returned within a predetermined time parameter. Ideal for
early onset dementia sufferers.
Alzheimer's: four main drugs availability to be limited
Health News Article | Reuters.com
"Britain's cost-effectiveness health watchdog said Tuesday it wants to limit access to the four main drugs used to treat patients with Alzheimer's disease, to the fury of pharmaceutical manufacturers. The National Institute for Clinical Excellence (NICE) recommended that doctors should stop giving the drugs to new patients because they are not cost effective.
NICE said three of the drugs were not recommended to treat mild to moderate dementia -- Pfizer Inc and Eisai Co.'s Aricept; Novartis AG's Exelon; and Reminyl, made by Johnson & Johnson and distributed in Britain by Shire Pharmaceuticals Group Plc.
"(They) are not recommended for use in the treatment of mild to moderate Alzheimer's disease," NICE said in a statement on its Web site (http://www.nice.org.uk/page.aspx?o=245908).
A fourth drug, Ebixa, made by Danish group Lundbeck, was not recommended for its designated treatment of moderately severe to severe Alzheimer's outside clinical trials.
Currently some 52,500 Britons are taking the drugs, known as cholinesterase inhibitors, at a cost of around 1,000 pounds ($1,922) per patient a year. Although they will be allowed to continue on treatment, the draft recommendations say the medicines should not be offered to new patients."
